Zambia
Tuberculosis profile
| High HIV burden |
Population  2013 15 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.6 (2.3–4.7) 25 (16–33)
Mortality (HIV+TB only) 8.6 (6.8–11) 59 (47–73)
Prevalence  (includes HIV+TB) 49 (28–76) 338 (193–524)
Incidence  (includes HIV+TB) 60 (56–64) 410 (387–440)
Incidence (HIV+TB only) 37 (35–40) 255 (240–274)
Case detection, all forms (%) 68 (64–72)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.3 (0–1.2) 8.1 (4.1–14)
MDR-TB cases among notified pulmonary
TB cases
88 (0–350) 570 (290–980)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 12 238   1 863
Pulmonary, clinically diagnosed 17 167    
Extrapulmonary 9 370    
       
Total new and relapse 40 638    
Previously treated, excluding relapses 5 155    
Total cases notified 45 793    
Among 40 638 new and relapse cases:
3 154 (8%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     79
Patients started on MDR-TB treatment     79
TB/HIV 2013 Number (%)
TB patients with known HIV status 41 305 (90)
HIV-positive TB patients 25 476 (62)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 23 769 (93)
HIV-positive TB patients on antiretroviral therapy (ART) 16 945 (67)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 85
Previously treated cases, excluding relapse, registered in 2012 79
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 29
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.4
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 16
% Funded domestically 44%
% Funded internationally 56%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-05 Data: www.who.int/tb/data